Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 1999, p. 2969-2974, Vol. 43, No. 12
Public Health Research Institute, New York,
New York 10016
Received 19 July 1999/Returned for modification 25 August
1999/Accepted 29 September 1999
Antibacterial activities of gatifloxacin (AM1155), a new
C-8-methoxy fluoroquinolone, and two structurally related compounds, AM1121 and ciprofloxacin, were studied with an isogenic set of ten
quinolone-resistant, gyrA (gyrase) mutants of
Escherichia coli. To compare the effect of each mutation on
resistance, the mutant responses were normalized to those of wild-type
cells. Alleles exhibiting the most resistance to growth inhibition
mapped in
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Gatifloxacin Activity against Quinolone-Resistant
Gyrase: Allele-Specific Enhancement of Bacteriostatic and Bactericidal
Activities by the C-8-Methoxy Group
-helix 4, which is thought to lie on a GyrA dimer surface that interacts with DNA. The C-8-methoxy group lowered the resistance due to these mutations more than it lowered resistance arising from
several gyrA alleles located outside
-helix 4. These
data are consistent with
-helix 4 being a distinct portion of the quinolone-binding site of GyrA. A helix change to proline behaved more
like nonhelix alleles, indicating that helix perturbation differs from
the other changes at helix residues. Addition of a parC
(topoisomerase IV) resistance allele revealed that the C-8-methoxy
group also facilitated attack of topoisomerase IV. When lethal effects
were measured at a constant multiple of the minimum inhibitory
concentration for each fluoroquinolone to normalize for differences in
bacteriostatic action, gatifloxacin was more potent than the C-8-H
compounds, both in the presence and absence of protein synthesis (an
exception was observed when alanine was substituted for aspartic acid
at position 82). Collectively, these data show that the C-8-methoxy
group contributes to the enhanced activity of gatifloxacin against
resistant gyrase and wild-type topoisomerase IV.
*
Corresponding author. Mailing address: Public Health
Research Institute, 455 First Ave., New York, NY 10016. Phone: (212) 578-0830. Fax: (212) 578-0804. E-mail:
drlica{at}phri.nyu.edu.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |